Cargando…

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies

BACKGROUND: To evaluate safety, pharmacokinetics, and maximum tolerated dose of roniciclib in patients with advanced malignancies, with dose expansion to evaluate clinical benefit at the recommended phase II dose (RP2D). METHODS: Two phase I dose-escalation studies evaluated two roniciclib dosing sc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bahleda, Rastislav, Grilley-Olson, Juneko E, Govindan, Ramaswamy, Barlesi, Fabrice, Greillier, Laurent, Perol, Maurice, Ray-Coquard, Isabelle, Strumberg, Dirk, Schultheis, Beate, Dy, Grace K, Zalcman, Gérard, Weiss, Glen J, Walter, Annette O, Kornacker, Martin, Rajagopalan, Prabhu, Henderson, David, Nogai, Hendrik, Ocker, Matthias, Soria, Jean-Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518866/ https://www.ncbi.nlm.nih.gov/pubmed/28463960 http://dx.doi.org/10.1038/bjc.2017.92

Ejemplares similares

Activity of roniciclib in medullary thyroid cancer
por: Lin, Shu-Fu, et al.
Publicado: (2018)

Effects of roniciclib in preclinical models of anaplastic thyroid cancer
por: Lin, Shu-Fu, et al.
Publicado: (2017)

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
por: Négrier, Sylvie, et al.
Publicado: (2017)

Roniciclib down-regulates stemness and inhibits cell growth by inducing nucleolar stress in neuroblastoma
por: Ognibene, Marzia, et al.
Publicado: (2020)

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours
por: Strumberg, D, et al.
Publicado: (2008)

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
por: Greillier, Laurent, et al.
Publicado: (2016)

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study
por: Schultheis, B., et al.
Publicado: (2013)

Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?
por: Ellinghaus, Peter, et al.
Publicado: (2022)

Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?
por: Gazzah, Anas, et al.
Publicado: (2013)

Personalised medicine for nonsmall cell lung cancer
por: Mascaux, Céline, et al.
Publicado: (2017)

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer
por: Travert, Camille, et al.
Publicado: (2019)

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2
por: Bahleda, Rastislav, et al.
Publicado: (2018)

Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases
por: Tomasini, Pascale, et al.
Publicado: (2019)

Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review
por: Roulleaux Dugage, Matthieu, et al.
Publicado: (2021)

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
por: Borget, Isabelle, et al.
Publicado: (2014)

Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
por: Kim, R D, et al.
Publicado: (2018)

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas
por: Coveler, Andrew L, et al.
Publicado: (2023)

Improved Tumor Purity Metrics in Next-generation Sequencing for Clinical Practice: The Integrated Interpretation of Neoplastic Cellularity and Sequencing Results (IINCaSe) Approach
por: Patel, Nirali M., et al.
Publicado: (2019)

Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration
por: Hu-Lieskovan, Siwen, et al.
Publicado: (2021)

Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours
por: Bahleda, Rastislav, et al.
Publicado: (2015)

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
por: Boyer, Arnaud, et al.
Publicado: (2018)

Real de-escalation or escalation in disguise?
por: Banys-Paluchowski, Maggie, et al.
Publicado: (2023)

Manual Washington® de oncología /
por: Govindan, Ramaswamy
Publicado: (2016)

Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma
por: Boutros, Celine, et al.
Publicado: (2020)

A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer
por: Volovat, Simona Ruxandra, et al.
Publicado: (2020)

Sinonasal Squamous Cell Carcinoma Survival Outcomes Following Induction Chemotherapy vs Standard of Care Therapy
por: Murr, Alexander T., et al.
Publicado: (2022)

Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer
por: Mross, Klaus, et al.
Publicado: (2011)

A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
por: Ramasamy, Karthik, et al.
Publicado: (2021)

Escalation and de-escalation of mechanical circulatory support in cardiogenic shock
por: Bertoldi, Letizia F, et al.
Publicado: (2021)

Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer
por: Scagliotti, Giorgio, et al.
Publicado: (2010)

Molecular profile of lung cancer in never smokers
por: Subramanian, Janakiraman, et al.
Publicado: (2013)

Untangling the evolutionary roots of lung cancer
por: Devarakonda, Siddhartha, et al.
Publicado: (2019)

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
por: Strumberg, D, et al.
Publicado: (2012)

Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data
por: Benzekry, Sébastien, et al.
Publicado: (2021)

Safety, Efficacy and Pharcacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/IIa Study
por: Schultheis, Beate, et al.
Publicado: (2020)

Escales Flute concerto ; Paris : suite symphonique /
por: Ibert, Jacques, 1890-1962
Publicado: (1994)

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
por: Adenis, A, et al.
Publicado: (2013)

Covid-19 escalates
por: Vaughan, Adam
Publicado: (2020)

Escalation Huddles: Facilitating Sepsis Activations Using Hospital-wide Escalation Processes
por: Lockwood, Justin, et al.
Publicado: (2018)

Escalate and De-Escalate Therapies for Intracranial Pressure Control in Traumatic Brain Injury
por: Battaglini, Denise, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e6bbpv46gsu1vfqnff7ju4qqd7